Daily interferon alpha-2B and ribavirin combination therapy for liver transplant patients with chronic hepatitis C infection.
Beckebaum
S
S
Department of General Surgery and Transplantation, University Hospital Essen, Essen, Germany. susanne.beckebaum@uni-essen.de
Cicinnati
V R
VR
Karliova
M
M
Dirsch
O
O
Erim
Y
Y
Frilling
A
A
Malago
M
M
Broelsch
C E
CE
Treichel
U
U
Gerken
G
G
D000998:Antiviral Agents / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D019698:Hepatitis C, Chronic / Q000188:drug therapy* / Q000601:surgery*; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use*; D008111:Liver Function Tests; D016031:Liver Transplantation; D008297:Male; D008875:Middle Aged; D016133:Polymerase Chain Reaction; D011183:Postoperative Complications / Q000188:drug therapy / Q000821:virology; D012367:RNA, Viral / Q000097:blood; D011994:Recombinant Proteins; D012008:Recurrence; D012254:Ribavirin / Q000627:therapeutic use*; D016896:Treatment Outcome; D019562:Viral Load
D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D012367:RNA, Viral; D011994:Recombinant Proteins; D012254:Ribavirin